RJA
VKTX icon

Raymond James & Associates’s Viking Therapeutics VKTX Stock Holding History

Raymond James & Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$28M Buy
441,590
+133,144
+43% +$7.81M 0.02% 654
2024
Q2 		$16.4M Buy
308,446
+63,206
+26% +$4.14M 0.01% 874
2024
Q1 		$20.1M Buy
245,240
+107,657
+78% +$4.79M 0.01% 775
2023
Q4 		$2.56M Buy
137,583
+68,921
+100% +$901K ﹤0.01% 1953
2023
Q3 		$760K Buy
68,662
+150
+0.2% +$2.15K ﹤0.01% 2639
2023
Q2 		$1.11M Buy
68,512
+22,541
+49% +$472K ﹤0.01% 2406
2023
Q1 		$765K Sell
45,971
-47,896
-51% -$495K ﹤0.01% 2636
2022
Q4 		$882K Sell
93,867
-10,861
-10% -$48.5K ﹤0.01% 2507
2022
Q3 		$285K Sell
104,728
-8,281
-7% -$27.1K ﹤0.01% 3214
2022
Q2 		$327K Sell
113,009
-10,742
-9% -$26.6K ﹤0.01% 3179
2022
Q1 		$371K Sell
123,751
-13,464
-10% -$48.3K ﹤0.01% 3264
2021
Q4 		$631K Sell
137,215
-114,121
-45% -$640K ﹤0.01% 2923
2021
Q3 		$1.58M Sell
251,336
-8,085
-3% -$49.9K ﹤0.01% 2263
2021
Q2 		$1.55M Sell
259,421
-142,309
-35% -$845K ﹤0.01% 2282
2021
Q1 		$2.54M Buy
401,730
+108,349
+37% +$762K ﹤0.01% 1852
2020
Q4 		$1.65M Sell
293,381
-86,935
-23% -$527K ﹤0.01% 2014
2020
Q3 		$2.21M Buy
380,316
+272
+0.1% +$1.87K ﹤0.01% 1696
2020
Q2 		$2.74M Buy
380,044
+120,986
+47% +$803K ﹤0.01% 1537
2020
Q1 		$1.21M Sell
259,058
-2,714
-1% -$16.7K ﹤0.01% 1860
2019
Q4 		$2.1M Sell
261,772
-71,220
-21% -$519K ﹤0.01% 1797
2019
Q3 		$2.29M Sell
332,992
-81
-0% -$602 ﹤0.01% 1693
2019
Q2 		$2.77M Buy
333,073
+3,347
+1% +$28.6K ﹤0.01% 1599
2019
Q1 		$3.28M Buy
329,726
+164,457
+100% +$1.38M 0.01% 1449
2018
Q4 		$1.26M Buy
165,269
+22,122
+15% +$264K ﹤0.01% 1953
2018
Q3 		$2.49M Buy
+143,147
New +$1.7M ﹤0.01% 1683

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Raymond James & Associates's VKTX Position: Q3 2024 in Review

Raymond James & Associates increased its Viking Therapeutics (VKTX) stake by 43% in Q3 2024, buying an estimated $7.81M and bringing the position to 441,590 shares worth $28M. The position accounts for 0.02% of the portfolio, ranked #654.

Raymond James & Associates first reported a position in VKTX in Q3 2018 and has held it in 25 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Raymond James & Associates held 441,590 shares of Viking Therapeutics worth $28M as of Q3 2024.
  • Raymond James & Associates bought 133,144 Viking Therapeutics shares in Q3 2024, an estimated $7.81M.
  • Viking Therapeutics made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #654 holding.
  • Raymond James & Associates first reported a position in Viking Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.